Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: StocksDATsoar who wrote (28850)	2/18/2000 8:21:00 AM
From: stu fabian	Respond to of 150070

anybody using money.net for quotes, and unable to get in????? thanks, Stu

To: StocksDATsoar who wrote (28850)	2/18/2000 11:21:00 AM
From: Katie Kommando	Read Replies (1) \| Respond to of 150070

200MPH . . . are you still in ADVR . . . today's news: (BSNS WIRE) Advanced Viral Research Corp. Receives Approval in Argentina Advanced Viral Research Corp. Receives Approval in Argentina for Human Clinical Studies With Antiviral "Substance R" Health/Medical & Biotechnology Writers YONKERS, N.Y.--(BW HealthWire)--Feb. 18, 2000-- Research Shows Drug Inhibits Production of CCR5, Stimulates the Immune System & Interferes with Viral Replication to Fight AIDS, HPV & Other Diseases Advanced Viral Research Corp. (OTCBB:ADVR) today announced that Substance R, its non-toxic peptide nucleic acid (PNA) immunomodulator, has received formal approval for Phase I human clinical studies in Argentina. Substance R (Panar 097, Reticulose(TM)), is a non-toxic peptide nucleic acid being developed by the company as a broad spectrum antiviral drug. The drug shows promise for the treatment of viral infections such as AIDS and Human Papilloma Virus (HPV), and autoimmune diseases like rheumatoid arthritis and diabetes mellitus. Peptide nucleic acids are stable analogues of genes and have applications as genomics. Advanced Viral Research Corp. laboratory studies have shown that Substance R inhibits the production of both the CCR5 and CXCR4 chemokine receptors, the key cellular co-receptors for the human immunodeficiency virus (HIV). "The approval of human trials in Argentina is a very important step on the road to making Substance R available for clinical use worldwide," said Shalom Z. Hirschman, M.D., President and Chief Executive Officer of Advanced Viral Research Corp. "Working with our scientific colleagues in Argentina, we have successfully laid the groundwork to move our application through ANMAT (the Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica -- National Administration for Drug, Food and Medical Technology), so that we may market Substance R in their country, helping to alleviate the suffering of people with a variety of debilitating diseases. I am especially gratified that the clinical approvals are progressing as planned in Argentina while we prepare our applications to the FDA in the United States," Dr. Hirschman stated. Clinical trials in patients with AIDS and HPV (the cause of genital warts and a critical factor in the development of cervical cancer) are planned in Argentina. The approval for human clinical tests in Argentina also paves the way for future study of the therapeutic effects of Substance R in other important diseases, such as rheumatoid arthritis and diabetes mellitus. Substance R is a second-generation therapeutic. Its predecessor was developed in the early 1900s. Using modern medical technology, scientists at The Advanced Viral Research Institute have refined the PNA preparation and pharmaceutical production, making today's About The Advanced Viral Research Institute Advanced Viral Research Corp.'s foundation begins with a dedication to scientific research and cutting-edge innovation. In that spirit, the company created The Advanced Viral Research Institute to foster individual scientific inquiry and creativity. Here, a respected team of molecular biologists, immunologists and other scientists conduct biomedical research in an academically oriented environment. Recent successes include identifying Substance R's mechanism of action, which will help with the company's planned Investigational New Drug (IND) application to the FDA. The Advanced Viral Research Institute also is developing other PNA-based therapeutics. About Advanced Viral Research Corp. Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm committed to researching, developing and bringing to market new, effective therapies for viral and other diseases, which will lead to the alleviation of human suffering and diseases worldwide. Its flagship drug, Substance R (Reticulose(TM)), is a non-toxic immunomodulator that has been shown to have beneficial therapeutic effects against viral diseases such as AIDS. Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by ADVR. Substance R (Reticulose(TM)) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. --30--ac/ny* CONTACT: Bratskeir & Company Mike Rosen / Jill Miller 212-679-2233 mrosen@bratskeir.com jmiller@bratskeir.com